Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.57), $0.24 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $71.9 million versus the consensus estimate of $65.88 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.